LENSAR INC LNSRV 深 滬
已收盤 09-21 16:00:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 0
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
LENSAR, Inc. announced that its second quarter 2026 financial results will be released before market open on Thursday, August 13, 2026. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results, recent highlights, and strategic initiatives. Participants can register via the provided link, and the webcast will be available on the company’s Investor Relations website. LENSAR specializes in advanced rob...
08-06 12:00
LENSAR Appoints Interim CFO, Accelerates Governance Timeline
An announcement from LENSAR ( ($LNSR) ) is now available. On May 25, 2026, LENS...
05-30 05:03
Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026
On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial officer, effective as of
05-30 04:09
LENSAR Q1 Sales $13.428M Miss $13.450M Estimate
LENSAR (NASDAQ:LNSR) reported quarterly sales of $13.428 million which missed the analyst consensus estimate of $13.450 million by 0.16 percent. This is a 5.16 percent decrease over sales of $14.159 million the same
05-08 19:01
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company, announced that its first quarter 2026 financial results will be released on May 8, 2026, followed by a conference call and webcast at 8:30 am ET. The company specializes in advanced robotic laser solutions for cataract treatment, including its ALLY Robotic Cataract Laser System™, which integrates AI and dual-modality laser technology to enhance surgical outcomes and efficiency.
04-30 11:00
Tenax Therapeutics names new CFO
Tenax Therapeutics (TENX) appointed Thomas R. Staab II as CFo, effective May 11, 2026, replacing interim CFO Thomas McGauley. Staab brings more than 25 years of financial leadership experience in the ...
04-22 19:18
LENSAR Announces Upcoming Chief Financial Officer Transition
LENSAR ( ($LNSR) ) has issued an update. LENSAR, Inc., a medical device company...
04-16 05:20
LENSAR's Thomas R. Staab, II To Resign As CFO Effective May 8, 2026; Co Commences Search For New Chief Financial Officer
On April 10, 2026, Thomas R. Staab, II, Chief Financial Officer of LENSAR, Inc. (the "Company"), notified the Company of his intention to resign from this position, effective May 8, 2026 (the "Transition Date"), to
04-16 04:36
